Skip to main content

Table 2 Comparison of parameters between 52 weeks-remission and 52 weeks-non remission groups at 4 weeks of TCZ therapy

From: Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

  DAS CDAI
R NR p R NR p
ROM 340 ± 90.8 322 ± 65.4 0.566 343 ± 101 330 ± 67.7 0.644
CRP 0.615 ± 1.36 0.612 ± 1.00 0.995 0.454 ± 0.810 0.762 ± 1.61 0.413
MMP-3 234 ± 190 206 ± 164 0.683 204 ± 186 251 ± 182 0.411
TJC 2.7 ± 3.2 2.4 ± 2.2 0.773 1.6 ± 1.7 3.4 ± 3.4 0.052
SJC 1.8 ± 2.6 2.3 ± 2.6 0.593 1.1 ± 2.1 2.5 ± 2.8 0.094
HAQ 0.592 ± 0.532 0.825 ± 0.712 0.267 0.343 ± 0.366 0.895 ± 0.606 0.001**
  1. TCZ, tocilizumab; ROM, reactive oxygen metabolites; CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; TJC, tender joint count; SJC, swollen joint count; HAQ, health assessment questionnaire; DAS, disease activity score; CDAI, clinical disease activity index; R, remission; NR, non-remission. Values are expressed as mean ± SD. Significantly different between remission and non-remission groups, **p < 0.01